SG10201803294PA - Tau imaging probe - Google Patents

Tau imaging probe

Info

Publication number
SG10201803294PA
SG10201803294PA SG10201803294PA SG10201803294PA SG10201803294PA SG 10201803294P A SG10201803294P A SG 10201803294PA SG 10201803294P A SG10201803294P A SG 10201803294PA SG 10201803294P A SG10201803294P A SG 10201803294PA SG 10201803294P A SG10201803294P A SG 10201803294PA
Authority
SG
Singapore
Prior art keywords
tau
imaging probe
low
tau imaging
none
Prior art date
Application number
SG10201803294PA
Inventor
Yukitsuka Kudo
Nobuyuki Okamura
Shozo Furumoto
Original Assignee
Clino Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clino Ltd filed Critical Clino Ltd
Publication of SG10201803294PA publication Critical patent/SG10201803294PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

TAU IMAGING PROBE An obj ect of the present invention is to provide a compound represented by formula (I) which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or undetected toxicity. 10 (1) Figure for publication: None 173
SG10201803294PA 2013-10-22 2014-10-22 Tau imaging probe SG10201803294PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013233470 2013-10-22

Publications (1)

Publication Number Publication Date
SG10201803294PA true SG10201803294PA (en) 2018-06-28

Family

ID=52992954

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201603131RA SG11201603131RA (en) 2013-10-22 2014-10-22 Tau imaging probe
SG10201803294PA SG10201803294PA (en) 2013-10-22 2014-10-22 Tau imaging probe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201603131RA SG11201603131RA (en) 2013-10-22 2014-10-22 Tau imaging probe

Country Status (13)

Country Link
US (1) US20160244411A1 (en)
EP (1) EP3061748A4 (en)
JP (1) JPWO2015060365A1 (en)
KR (1) KR20160072226A (en)
CN (1) CN105814023A (en)
AU (1) AU2014338155B2 (en)
BR (1) BR112016008871A8 (en)
CA (1) CA2928313A1 (en)
IL (1) IL245221A0 (en)
MX (1) MX2016005233A (en)
RU (1) RU2016119524A (en)
SG (2) SG11201603131RA (en)
WO (1) WO2015060365A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522414D0 (en) * 2015-12-18 2016-02-03 Clino Ltd Monoamine oxidase B binders
EP3484528B1 (en) * 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
EP3652329B1 (en) * 2017-07-12 2023-10-04 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
CN107488144B (en) * 2017-08-09 2021-06-04 复旦大学 Molecule capable of specifically binding and inhibiting Tau protein aggregation and preparation method and application thereof
JP7284490B2 (en) 2018-08-07 2023-05-31 国立大学法人東北大学 Monoamine oxidase B imaging probe
KR20210128125A (en) * 2020-04-16 2021-10-26 연세대학교 산학협력단 A Contrast Agent Composition for Detecting Lesional Margin of Dementia Caused by Degenerative Brain Disease Comprising Quinoline Derivatives as Active Ingredients
KR102369838B1 (en) * 2020-04-16 2022-03-04 연세대학교 산학협력단 A Contrast Agent Composition for Detecting Lesional Margin of Astrocytosis-Related Disease Comprising Quinoline Derivatives as Active Ingredients
CN111892534A (en) * 2020-08-04 2020-11-06 中国科学技术大学 pH-sensitive fluorescent probe, and preparation method and application thereof
CN113754583A (en) * 2021-09-03 2021-12-07 湖南工程学院 2- ([2, 2' -biquinolyl ] -3-ether) -1-ethanol and derivative and synthetic method thereof
CN113999172A (en) * 2021-11-17 2022-02-01 湖南工程学院 2- ((2-phenylquinoline-3-yl) ether) -1-ethanol and derivative and synthetic method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574500A1 (en) 2002-12-16 2005-09-14 BF Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
US8483197B2 (en) * 2009-03-23 2013-07-09 Qualcomm Incorporated AP to legacy station SDMA protocol
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2411057B1 (en) * 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
KR101101977B1 (en) 2009-04-09 2012-01-02 (주)에스메디 2-aryl naphthalene, 2-aryl quinoline derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and phrmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient
WO2012057312A1 (en) * 2010-10-29 2012-05-03 クリノ株式会社 Tau imaging probe
RU2013125326A (en) * 2010-11-16 2014-12-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД HETEROCYCLIC COMPOUNDS AS PROBES FOR VISUALIZING TAU PATHOLOGY
GB201411571D0 (en) * 2014-06-30 2014-08-13 Ge Healthcare Ltd Radiolabelling method

Also Published As

Publication number Publication date
WO2015060365A1 (en) 2015-04-30
EP3061748A1 (en) 2016-08-31
RU2016119524A (en) 2017-11-28
EP3061748A4 (en) 2017-04-05
AU2014338155A1 (en) 2016-05-19
SG11201603131RA (en) 2016-05-30
IL245221A0 (en) 2016-06-30
US20160244411A1 (en) 2016-08-25
JPWO2015060365A1 (en) 2017-03-09
AU2014338155B2 (en) 2018-08-23
BR112016008871A8 (en) 2020-03-24
RU2016119524A3 (en) 2018-06-14
MX2016005233A (en) 2017-01-05
CA2928313A1 (en) 2015-04-30
CN105814023A (en) 2016-07-27
KR20160072226A (en) 2016-06-22

Similar Documents

Publication Publication Date Title
SG10201803294PA (en) Tau imaging probe
EA201890899A1 (en) PHARNESIDE X-RECEPTOR MODULATORS
IN2015MN00404A (en)
MY180083A (en) Tetrahydropyrrolothiazine compounds
IN2015MN00405A (en)
MX2016014615A (en) Deuterated heterocyclic compounds and their use as imaging agents.
MA38583B1 (en) Derivatives of dolastatin 10 and auristatines
CR20140468A (en) DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS
EA201591503A1 (en) NAFTHYRIDINE DERIVATIVES, USEFUL AS ANTAGONISTS ALPHA-V-BETA-6 INTEGRINA
BR112016011755A2 (en) derived from urea or pharmacologically acceptable salt thereof
RS54730B1 (en) Inhibitors of beta-secretase
CY1118883T1 (en) METHOD OF PREPARATION OF BORTIOXETINE
RS54526B1 (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
IN2015DN02930A (en)
CR20140306A (en) FLUORMETIL -5,6-DIHIDRO-4H- [1,3] OXAZINES
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
EA201591815A1 (en) BICYCLO [2.2.2] ACIDS - GPR120 MODULATORS
JOP20200030A1 (en) Pentacyclic compound
AR095097A1 (en) PHENOXYETOXI COMPOUNDS
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
IN2013MU03862A (en)
BR112015023270A2 (en) polycyclic pyrazolinone derivative and herbicide comprising the same as an effective component
UY37443A (en) PHENYLAMINE DERIVATIVES REPLACED IN POSITION 4 AND USE OF THE SAME TO PROTECT CROPS BY COMBATING UNWANTED PHYTOOPATHOGEN MICROORGANISMS
EP3769757A3 (en) Imaging histone deacetylases with a radiotracer using positron emission tomography